Navigation Links
Hope for a more effective and less toxic cancer drug

Detailed evaluation conducted at WEHI into a possible new cancer drug suggests that it may prove to be more effective and less toxic than current chemotherapeutic drugs.

Dr David Huang, Dr Andrew Roberts, Prof Jerry Adams and their teams from WEHI's cancer research divisions have been assessing the potential of a new compound, ABT-737, that was developed by US-based healthcare company, Abbott.

Under normal circumstances, human cells have a limited lifespan. They die when they are damaged, worn out or no longer needed by the body. When they die, these cells are replaced by new ones. The body depends on a normal and healthy process called programmed cell death - or apoptosis - to ensure that unwanted cells die on cue. If this process fails, then the damaged cells live on and multiply indefinitely and uncontrollably. This uncontrolled multiplication of rogue cells can lead to cancer.

Conventional chemotherapeutic drugs target and attempt to kill rapidly dividing cancer cells. This is sometimes successful in halting the disease, but these drugs inevitably damage many normal tissues. Hence, even when the chemotherapy works, the side effects for the patient can be very serious.

ABT-737 is a drug with a different strategy for attacking cancer. Rather than attempting to poison the rogue cells, the new drug attempts to reactivate the healthy and normal cell death program that failed to kill the unwanted cells on cue.

WEHI's leading researcher with the assessment project, Dr David Huang, explains, "Normally, the cell death machinery is switched on when damaged cells need to be removed. The failure of the machinery to be turned on when it should can lead to cancer. ABT-737 is a 'switch flicker' that kicks the cell death machinery into action. Much more remains to be done to assess the drug's safety and effectiveness in patients, but early results from the laboratory are promising. Our hope is that the new drug will prove to be more effective while having fewer side effects."

The findings of the scientific assessment team are published in the 13 November 2006 issue of the prestigious international journal Cancer Cell.


'"/>

Source:Research Australia


Related biology news :

1. Combination therapy boosts effectiveness of telomere-directed cancer cell death
2. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
3. Boosting HIV screening can increase survival and is cost effective
4. Live vaccines more effective against horse herpes virus
5. Man-made wetlands effectiveness similar to natural marsh
6. Wake Forest scientists find new combination vaccine effective against plague
7. UCLA study assesses cost-effectiveness of Hepatitis B drugs
8. New study: Sexually transmitted disease treatment can be effectively administered by sex partners
9. New vaccine protects more effectively against tuberculosis
10. Harmless virus may hold key to more effective HIV drug discovery
11. Structures of marine toxins provide insight into their effectiveness as cancer drugs
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... According to a new market research report "Emotion Detection ... Voice Recognition), Service, Application Area, End User, And Region - Global Forecast to ... 6.72 Billion in 2016 to USD 36.07 Billion by 2021, at a Compound ... ... MarketsandMarkets Logo ...
(Date:12/7/2016)... , Dec. 7, 2016   Avanade ... successful Formula One teams in history, exploit biometric data ... stop performance and maintain the competitive edge against their ... 2016. Avanade has worked with Williams ... range of biometric data (heart rate, breathing rate, temperature ...
(Date:12/6/2016)... WARSAW, Ind. , Dec. 6, 2016  Zimmer Biomet ... that it has priced an offering of €500.0 million principal ... €500.0 million principal amount of its 2.425% senior unsecured notes ... is expected to occur on December 13, 2016, subject to the ... on an annual basis. ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... OXFORD, England , December 8, 2016 ... Company, has expanded its customisable SureSeq™ NGS panel range with ... - allowing fast and cost-effective study of variants in familial ... copy number variation (CNV) detection on a single small panel ... and hotspot content. This includes all exons for LDLR ...
(Date:12/8/2016)... ... December 08, 2016 , ... KBioBox llc announced ... client demand KbioBox developed a sophisticated “3 click” gene dditing off target analysis ... KBioBox’s new website, https://www.kbiobox.com/ and powered by the company’s proprietary ...
(Date:12/8/2016)... ... December 08, 2016 , ... Microbial genomics leader, ... uBiome is one of just six company finalists in the Health & Medicine ... uBiome, companies nominated as finalists in this year’s awards include Google, SpaceX, Oculus, ...
(Date:12/8/2016)... 2016  Soligenix, Inc. (OTCQB: SNGX) (Soligenix or ... developing and commercializing products to treat rare diseases ... today the long-term follow-up data from its Phase ... Innate Defense Regulator (IDR), in the treatment of ... patients undergoing chemoradiation therapy (CRT).  The additional 12-month ...
Breaking Biology Technology: